GoodRx Q3 2023 Earnings Report
Key Takeaways
GoodRx's third quarter 2023 results showed a revenue of $180.0 million, a decrease of 4% compared to the previous year. Adjusted Revenue increased by 1% to $190.0 million. The company reported a net loss of $38.5 million and an Adjusted EBITDA of $53.5 million.
Revenue of $180.0 million; Adjusted Revenue of $190.0 million.
Net loss of $38.5 million; Adjusted Net Income of $25.5 million.
Adjusted EBITDA of $53.5 million.
Exited the quarter with over 7 million consumers of prescription-related offerings.
GoodRx
GoodRx
Forward Guidance
GoodRx is guiding to fourth quarter revenue and Adjusted Revenue in the range of $188 million to $194 million, representing 2%-5% year-over-year growth, and Adjusted EBITDA Margin in the mid-to-high twenty-percent range. They expect their 2024 Adjusted EBITDA Margin to meet or exceed 4Q23.
Positive Outlook
- Fourth quarter revenue and Adjusted Revenue in the range of $188 million to $194 million, representing 2%-5% year-over-year growth
- Adjusted EBITDA Margin in the mid-to-high twenty-percent range
- The business is expected to grow next year at a roughly similar rate to the growth rate implied in the 4Q23 guide
- 2024 Adjusted EBITDA Margin is expected to meet or exceed 4Q23
- Balance sheet and liquidity position remained strong in the third quarter, while generating healthy cash flow from operations